Synapse - Nishant Mishra

Nishant Mishra

Research Focus

Former Employee. Biostat/Epidemiology; Data Analyst

Recent additions – View all

The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
Journal Article

Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
Clinical Cancer Research (2017)

Fulltext@MSK | Save
Veliparib (ABT-888), bendamustine, and rituximab (VBR) is well tolerated and efficacious in patients with lymphoma: Final analysis of a phase 1b clinical trial of VB and a cohort expansion of VBR in patients with B-cell lymphoma
Meeting Abstract

Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Younes, A.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; more...
Blood (2015)

Fulltext@MSK | Save

Co-authors at MSK

2

France
2

Gerecitano
2

Hamlin
2

Horwitz
2

Jarjies
2

Matasar
2

Moskowitz
2

Moskowitz
2

Noy
2

Palomba
2

Portlock
2

Soumerai
2

Straus
2

Younes
2

Zelenetz
1

Carvajal
1

Dang
1

Fury
1

Gajria
1

Gounder
1

Ho
1

Hyman
1

Konner
1

Voss
1

Whang
1

Zhang

Types of Work

Publications

Blood (1)
Clinical Cancer Research (1)